In late June 2026, an official decree on how France will govern the reimbursement of medical cannabis was reportedly submitted to the French Council of State, as the Union of Manufacturers for the Utilization of Hemp Extracts (UIVEC) announced at the time.
Laurent Panifous confirmed on 30 June that the Ministry of Economy had approved the decree on rules for the coverage of marijuana-based medicine, which was finalised mid-June. This text which is vital for the transition to permanent framework will be sent by the Council of State to be examined after the summer holiday and published at the beginning of school. UIVEC posted on LinkedIn in English, after being translated from French.
It appears that there has been no movement in the matter since the announcement of the official decret being submitted to Council of State. This has led to logical questions about the current status in France of medical cannabis regulation.
Newsweed was not able to confirm if the deeds sent to the Council of State as announced were delivered. Newsweed In its reporting, the newspaper wrote: Newsweed wrote: “When Newsweed contacted the Ministry of Health or several people close to or involved in the matter, they did not respond at the publication of this story.”
“The current impasse has been difficult to pinpoint. But some attribute it directly to the Ministry of Health. They are reluctant to legalize medical use of marijuana while the government prioritises the fight against drugs trafficking.” The outlet wrote that the government prioritizes fighting drug trafficking.
The medical cannabis reimbursement plan in France, once it reaches the finish line, will cover medical cannabis treatments for neuropathic, epilepsy and multiple sclerosis pains, as well as oncology related refractory symptoms. It is also expected to cover advanced palliative treatment.
According to a survey conducted by Norstat Institute on behalf of the patient association APAISER S&C and the newspaper L’Hemicycle92% respondents in the survey supported legalizing medical marijuana in France.
- 92% of respondents are in favor of the legalization of medical cannabis
- 72% support the use of medical cannabis to treat all conditions where cannabis is effective.
- 82% consider it to be ‘problematic’ that medical cannabis access remains limited in France
- 79% believe that public debates are still hampered by misunderstandings
- 73% say that French authorities don’t take the suffering of patients into consideration enough
- Only 11% believe medical cannabis’ effectiveness ‘remains too uncertain to justify its medical use’
These results confirm what we’ve observed for years: that the public is moving beyond taboos and focusing on the health of patients. Now, they expect the decision makers to be responsible and give patients access to existing treatments, which work and are currently denied. said Mado Gilanton, President of APAISER S&C.
Sponsored Content
This informative article is brought to you by NUBO CBD →